Oruka Therapeutics (NASDAQ:ORKA) Now Covered by Lifesci Capital

Investment analysts at Lifesci Capital initiated coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research note issued on Monday, Benzinga reports. The firm set an “outperform” rating and a $41.00 price target on the stock. Lifesci Capital’s target price indicates a potential upside of 61.04% from the stock’s current price.

Other analysts have also issued research reports about the stock. Wedbush initiated coverage on shares of Oruka Therapeutics in a research report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 price target on the stock. Jefferies Financial Group assumed coverage on Oruka Therapeutics in a research report on Friday. They set a “buy” rating and a $40.00 target price on the stock. Finally, TD Cowen assumed coverage on Oruka Therapeutics in a report on Monday. They issued a “buy” rating for the company.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock traded up $0.57 during mid-day trading on Monday, hitting $25.46. The company had a trading volume of 7,779 shares, compared to its average volume of 49,485. Oruka Therapeutics has a 12-month low of $18.72 and a 12-month high of $53.88.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.